The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Abingworth, Backed by Carlyle, Launches $1.5bn Fund for Clinical Trials
Dec 01, 2024•over 1 year ago
Contract Type
partnership
OuakaBiotechnology
Description
Abingworth, with the backing of Carlyle, is raising a fund worth up to $1.5bn to finance as many as eight late-stage clinical trials. The company has recently signed royalty deals with large pharmaceutical and biotech companies and aims to attract larger pharmaceutical companies for partnership opportunities.
Company Information
Company
Abingworth
Location
Ouaka, Central African Republic
About
Abingworth is a UK-based life sciences investor that focuses on financing late-stage clinical trials and forging partnerships with big pharmaceutical companies for a share of royalties from new drugs. Carlyle, a private equity group, acquired Abingworth in 2022.
OuakaBiotechnology